 |
| CrossRef Text and Data Mining |
| Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining. |
| Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors |
| Sangmo Hong, Chang Hee Jung, Song Han, Cheol-Young Park |
|
Diabetes Metab J. 2022;46(1):63-70. Published online April 19, 2021 DOI: https://doi.org/10.4093/dmj.2020.0253 |
|
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors Diabetes & Metabolism Journal. 2022;46(1):63-70  Dipeptidyl peptidase IV inhibitors Meyler's Side Effects of Drugs. 2016;1003 The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin Clinical Science. 2018;132(4):489-507 Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin Clinical Science. 2019;133(1):151-151 Controversy about the relative efficacy of dipeptidyl peptidase IV inhibitors Diabetologia. 2012;55(10):2848-2849 Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid Cellular Metabolism and Related Disorders. 2020; Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter FEBS Journal. 2011;278(18):3256-3276 Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin Journal of the European Academy of Dermatology and Venereology. 2011;26(2):249-253 Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy Drug, Healthcare and Patient Safety. 2010;7 What mediates the benefits associated with dipeptidyl peptidase-IV inhibition? Diabetologia. 2005;48(4):605-607 |
